Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension.

Trial Profile

Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2017

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Feb 2017 Results published in the Journal of Clinical Hypertension (Greenwich)
    • 09 Feb 2010 Actual initiation date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 14 Aug 2009 Results were reported at the 19th European Meeting on Hypertension, held in Milan, Italy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top